FSTX
Income statement / Annual
Last year (2021), F-star Therapeutics, Inc.'s total revenue was $21.17 M,
an increase of 88.05% from the previous year.
In 2021, F-star Therapeutics, Inc.'s net income was -$31.28 M.
See F-star Therapeutics, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
| Operating Revenue |
$21.17 M |
$11.26 M |
$28.32 M |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
$21.17 M
|
$11.26 M
|
$28.32 M
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit Ratio |
1
|
1
|
1
|
0
|
0
|
0
|
| Research and Development Expenses |
$28.75 M
|
$14.13 M
|
$31.39 M
|
$19.75 M
|
$13.08 M
|
$14.02 M
|
| General & Administrative Expenses |
$23.13 M
|
$19.51 M
|
$15.28 M
|
$8.72 M
|
$8.18 M
|
$5.74 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$23.13 M
|
$19.51 M
|
$15.28 M
|
$8.72 M
|
$8.18 M
|
$5.74 M
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$51.88 M
|
$33.64 M
|
$46.67 M
|
$28.47 M
|
$21.25 M
|
$19.76 M
|
| Cost And Expenses |
$51.88 M
|
$33.64 M
|
$46.67 M
|
$28.47 M
|
$21.25 M
|
$19.76 M
|
| Interest Income |
$0.00
|
$0.00
|
$0.00
|
$999.00 K
|
$369.00 K
|
$96.00 K
|
| Interest Expense |
$844.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$1.29 M
|
$1.14 M
|
$9.15 M
|
$288.00 K
|
$158.00 K
|
$118.00 K
|
| EBITDA |
-$29.42 M |
-$21.24 M |
-$13.35 M |
-$28.47 M |
-$21.25 M |
-$19.40 M |
| EBITDA Ratio |
-1.39
|
-1.89
|
-0.47
|
0
|
0
|
0
|
| Operating Income Ratio |
-1.45
|
-1.99
|
-0.79
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
-$941.00 K
|
-$3.24 M
|
-$1.60 M
|
$5.62 M
|
-$6.43 M
|
$2.04 M
|
| Income Before Tax |
-$31.66 M
|
-$25.62 M
|
-$23.75 M
|
-$22.85 M
|
-$27.68 M
|
-$17.37 M
|
| Income Before Tax Ratio |
-1.5
|
-2.28
|
-0.84
|
0
|
0
|
0
|
| Income Tax Expense |
-$372.00 K
|
-$1.00 K
|
-$737.00 K
|
$0.00
|
$0.00
|
$0.00
|
| Net Income |
-$31.28 M
|
-$25.62 M
|
-$23.01 M
|
-$22.85 M
|
-$27.68 M
|
-$17.37 M
|
| Net Income Ratio |
-1.48
|
-2.28
|
-0.81
|
0
|
0
|
0
|
| EPS |
-1.88 |
-2.82 |
-2.54 |
-1.6 |
-2.5 |
-2.4 |
| EPS Diluted |
-1.88 |
-2.82 |
-2.54 |
-1.6 |
-2.5 |
-2.4 |
| Weighted Average Shares Out |
$16.65 M
|
$9.09 M
|
$9.07 M
|
$14.62 M
|
$11.15 M
|
$7.26 M
|
| Weighted Average Shares Out Diluted |
$16.65 M
|
$9.09 M
|
$9.07 M
|
$14.62 M
|
$11.15 M
|
$7.26 M
|
| Link |
|
|
|
|
|
|
